Printer Friendly

THE LIPOSOME COMPANY DECLARES FIRST

 PRINCETON, N.J., March 11 /PRNewswire/ -- The Liposome Company, Inc. (NASDAQ: LIPO and LIPOZ) announced today that its board of directors has declared a quarterly cash dividend on its 7-3/4 percent Series A cumulative convertible exchangeable preferred stock at the prorated dividend rate of $.4844 per depositary share. The initial quarterly dividend is payable April 15, 1993 to stockholders of record on April 1, 1993. Dividends on the preferred stock accrue and are cumulative from the date of original issue, Jan. 15, 1993, at the annual rate of $1.9375 per depositary share. Subsequent dividends are payable in equal quarterly installments on the 15th days of July, October and January.
 A leading company dedicated exclusively to the development of liposome and lipid-based pharmaceuticals, The Liposome Company develops proprietary parenteral pharmaceuticals for the treatment, prevention, and diagnosis of life-threatening diseases. The Liposome Company has four drugs currently in clinical trials. ABLC(TM) is in Phase II/III studies for the treatment of systemic fungal infections; TLC G-65 is in Phase II trials in the U.S. and Phase III trials in Europe for the treatment of Mycobacterium avium-intracellulare (MAI), an infection that eventually strikes 30 to 50 percent of people with AIDS; TLC D-99 is in Phase II for treatment of matastatic breast cancer; and TLC C-53 has just completed Phase I trials in preparation for studies in Adult Respiratory Distress Syndrome.
 -0- 3/11/93
 /CONTACT: Anne M. Van Lent, senior vice president and CFO of The Liposome Company, 609-452-7060/
 (LIPO)


CO: The Liposome Company, Inc. ST: New Jersey IN: MTC SU: DIV

WB-AH -- NY045 -- 5168 03/11/93 14:29 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 11, 1993
Words:273
Previous Article:BIOMUNE SYSTEMS, INC. BOARD OF DIRECTORS APPROVES STOCK SPLIT, DIVIDENDS
Next Article:TRINITY INDUSTRIES, INC. ANNOUNCES QUARTERLY DIVIDEND
Topics:


Related Articles
THE LIPOSOME COMPANY NAMES TWO CLINICAL RESEARCH VPs
THE LIPOSOME COMPANY, INC. REPORTS FIRST QUARTER RESULTS
THE LIPOSOME COMPANY, INC. PROMOTES TWO EXECUTIVES; SILVERMAN, WILLIAMS NAMED TO NEW MANAGEMENT POSTS
WYETH-AYERST BEGINS TESTING LIPOSOMAL FLU VACCINE; THE LIPOSOME COMPANY'S NEW ADJUVANT MAY BOOST PROTECTION
THE LIPOSOME COMPANY DECLARES QUARTERLY DIVIDEND ON PREFERRED STOCK
THE LIPOSOME COMPANY DECLARES QUARTERLY DIVIDEND ON PREFERRED STOCK
LIPOSOME COMPANY DECLARES QUARTERLY DIVIDEND ON PREFERRED STOCK
THE LIPOSOME COMPANY DECLARES QUARTERLY DIVIDEND ON PREFERRED STOCK
THE LIPOSOME COMPANY DECLARES QUARTERLY DIVIDEND ON PREFERRED STOCK
The Liposome Company, Inc. Announces Redemption of Convertible Exchangeable Preferred Stock

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters